Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology
- PMID: 20164329
- PMCID: PMC6634531
- DOI: 10.1523/JNEUROSCI.5983-09.2010
Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology
Abstract
alpha-Synuclein (alpha-SYN) is a key player in the pathogenesis of Parkinson's disease (PD). In pathological conditions, the protein is present in a fibrillar, aggregated form inside cytoplasmic inclusions called Lewy bodies. Members of the FK506 binding protein (FKBP) family are peptidyl-prolyl isomerases that were shown recently to accelerate the aggregation of alpha-SYN in vitro. We now established a neuronal cell culture model for synucleinopathy based on oxidative stress-induced alpha-SYN aggregation and apoptosis. Using high-content analysis, we examined the role of FKBPs in aggregation and apoptotic cell death. FK506, a specific inhibitor of this family of proteins, inhibited alpha-SYN aggregation and neuronal cell death in this synucleinopathy model dose dependently. Knockdown of FKBP12 or FKBP52 reduced the number of alpha-SYN aggregates and protected against cell death, whereas overexpression of FKBP12 or FKBP52 accelerated both aggregation of alpha-SYN and cell death. Thus, FK506 likely targets FKBP members in the cell culture model. Furthermore, oral administration of FK506 after viral vector-mediated overexpression of alpha-SYN in adult mouse brain significantly reduced alpha-SYN aggregate formation and neuronal cell death. Our data explain previously described neuroregenerative and neuroprotective effects of immunophilin ligands and validate FKBPs as a novel drug target for the causative treatment of PD.
Figures






References
-
- Avramut M, Achim CL. Immunophilins and their ligands: insights into survival and growth of human neurons. Physiol Behav. 2002;77:463–468. - PubMed
-
- Avramut M, Zeevi A, Achim CL. The immunosuppressant drug FK506 is a potent trophic agent for human fetal neurons. Brain Res Dev Brain Res. 2001;132:151–157. - PubMed
-
- Brecht S, Schwarze K, Waetzig V, Christner C, Heiland S, Fischer G, Sartor K, Herdegen T. Changes in peptidyl-prolyl cis/trans isomerase activity and FK506 binding protein expression following neuroprotection by FK506 in the ischemic rat brain. Neuroscience. 2003;120:1037–1048. - PubMed
-
- Charters AR, Kobayashi M, Butcher SP. Immunochemical analysis of FK506 binding proteins in neuronal cell lines and rat brain. Biochem Soc Trans. 1994a;22:411S. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous